financetom
Business
financetom
/
Business
/
Crypto Exchange Gemini Boosts IPO Price Range to $24-$26 Per Share
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Crypto Exchange Gemini Boosts IPO Price Range to $24-$26 Per Share
Sep 10, 2025 1:12 PM

Gemini, the crypto exchange run by Tyler and Cameron Winklevoss, has boosted the price range for its planned Friday IPO, the company said in an updated S1 filing on Tuesday.

The firm now expects to sell 16.67 million shares between $24 and $26 each in the public offering versus the previous range of $17-$19. At the high end of the new range, Gemini would raise more than $430 million at about a $3.1 billion valuation.

Goldman Sachs ( GS ), Citigroup ( C/PN ), Morgan Stanley ( MS ) and Cantor are the lead underwriters on the IPO.

Crypto ( CRCW ) native companies are increasingly looking to go public under President Trump's more benign regulatory regime. Gemini's public listing follows that of rival exchange Bullish (BLSH), CoinDesk's owner, and stablecoin issuer Circle (CRCL).

Exchange giant Nasdaq (NDAQ) has entered into an agreement to buy $50 million of shares in a private placement at a per share price equal to the IPO price.

The stock will list on the Nasdaq Global Select Market under the ticker symbol GEMI.

Read more: Crypto Exchange Gemini Aims for $2.22B Valuation in U.S. IPO, Seeking to Raise $317M

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?
What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?
Jun 20, 2024
Shares of Tempest Therapeutics Inc ( TPST ) are trading lower on Thursday, with a session volume of 21 million as per data from Benzinga Pro. The company announced new data from the ongoing Phase 1b/2 clinical study on amezalpat2 (TPST-1120). The drug candidate delivered a six-month improvement in median overall survival advantage when combined with atezolizumab and bevacizumab compared to...
-- Empire Co. Brief: Up More Than 6% After Reporting Q4 EPS Normalized $0.63 Vs Forecast $0.62, And Saying It Plans To Be Cautious On Capital Spending Going Forward
-- Empire Co. Brief: Up More Than 6% After Reporting Q4 EPS Normalized $0.63 Vs Forecast $0.62, And Saying It Plans To Be Cautious On Capital Spending Going Forward
Jun 20, 2024
09:35 AM EDT, 06/20/2024 (MT Newswires) -- Price: 34.37, Change: +2.01, Percent Change: +6.21 ...
--Tests Show Instagram Shares Sexual Videos to Accounts for 13-Year-Olds, Wall Street Journal Says
--Tests Show Instagram Shares Sexual Videos to Accounts for 13-Year-Olds, Wall Street Journal Says
Jun 20, 2024
09:36 AM EDT, 06/20/2024 (MT Newswires) -- Price: 500.05, Change: +0.56, Percent Change: +0.11 ...
GlobalFoundries, BAE Systems Partner to Boost Supply of Essential Chips for National Security Programs
GlobalFoundries, BAE Systems Partner to Boost Supply of Essential Chips for National Security Programs
Jun 20, 2024
09:37 AM EDT, 06/20/2024 (MT Newswires) -- GlobalFoundries ( GFS ) and BAE Systems said Thursday that they have entered into a partnership to focus on US chip manufacturing and joint research and development for advanced chip technologies for national security programs. The companies said the partnership would include aligning technology roadmaps, conducting joint research and development in advanced semiconductor...
Copyright 2023-2026 - www.financetom.com All Rights Reserved